Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

[1]  K. Szekeres,et al.  Murine Pancreatic Adenocarcinoma Dampens SHIP-1 Expression and Alters MDSC Homeostasis and Function , 2011, PloS one.

[2]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[3]  Jason Y. Park,et al.  Molecular signatures of pancreatic cancer. , 2011, Archives of pathology & laboratory medicine.

[4]  S. Quezada,et al.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication , 2011, Immunological reviews.

[5]  S. Akira,et al.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.

[6]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[7]  T. Jacks,et al.  Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. , 2011, Cancer cell.

[8]  R. Hruban,et al.  The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting , 2011, The Journal of pathology.

[9]  D. Bar-Sagi,et al.  Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. , 2010, Cancer cell.

[10]  S. Bicciato,et al.  Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.

[11]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[12]  L. Coussens,et al.  Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.

[13]  E. Traggiai,et al.  Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF , 2009, European journal of immunology.

[14]  H. Bear,et al.  GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells , 2010, Breast Cancer Research and Treatment.

[15]  R. Vonderheide,et al.  Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. , 2009, Cancer letters.

[16]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[17]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[18]  G. Bhagat,et al.  Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. , 2008, Cancer cell.

[19]  D. Saur,et al.  A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors , 2008, Proceedings of the National Academy of Sciences.

[20]  J. Hamilton.  Colony-stimulating factors in inflammation and autoimmunity , 2008, Nature Reviews Immunology.

[21]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[22]  R. Hruban,et al.  Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection , 2008, Cancer biology & therapy.

[23]  T. Randall,et al.  Ectopic lymphoid tissues and local immunity. , 2008, Seminars in immunology.

[24]  B. Ancrile,et al.  Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. , 2008, Molecular interventions.

[25]  J. Leips,et al.  Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. , 2007, Cancer research.

[26]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[27]  Helmut Friess,et al.  Pancreatic cancer microenvironment , 2007, International journal of cancer.

[28]  Gerald C. Chu,et al.  Stromal biology of pancreatic cancer , 2007, Journal of cellular biochemistry.

[29]  M. Pfreundschuh,et al.  Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Bar-Sagi,et al.  Pancreatic duct epithelial cell isolation and cultivation in two-dimensional and three-dimensional culture systems. , 2006, Methods in enzymology.

[31]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[32]  E. Thorsby,et al.  CD8+T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (GLY13→ASP), are cytotoxic towards a carcinoma cell line harbouring the same mutation , 1995, Cancer Immunology, Immunotherapy.

[33]  B. Mroczko,et al.  Hematopoietic cytokines in the sera of patients with pancreatic cancer , 2005, Clinical chemistry and laboratory medicine.

[34]  M. Belosevic,et al.  Regulation of myeloid development and function by colony stimulating factors. , 2004, Developmental and comparative immunology.

[35]  E. Voest,et al.  Stimulation of angiogenesis by Ras proteins. , 2004, Biochimica et biophysica acta.

[36]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[37]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[38]  C. Wright,et al.  The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors , 2002, Nature Genetics.

[39]  S. Bézieau,et al.  A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion1 , 2002, The Journal of Immunology.

[40]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[41]  T. Ruzicka,et al.  Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. , 2000, The Journal of investigative dermatology.

[42]  P. Hwu,et al.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. , 1999, Journal of immunology.

[43]  S Weijzen,et al.  Modulation of the immune response and tumor growth by activated Ras , 1999, Leukemia.

[44]  H. Drexler,et al.  Secretion of functional hematopoietic growth factors by human carcinoma cell lines , 1998, International journal of cancer.

[45]  G. Gaudernack,et al.  Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer , 1998, Vox sanguinis.

[46]  D. Byrd,et al.  CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. , 1995, Cancer research.

[47]  M. Vadas,et al.  Transcriptional regulation of mouse granulocyte-macrophage colony-stimulating factor/IL-3 locus. , 1995, Journal of immunology.

[48]  E. Thorsby,et al.  T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA , 1994, European journal of immunology.